Le Lézard
Classified in: Health, Science and technology
Subject: ACC

Notice of annual general meeting in Cantargia AB (publ)


STOCKHOLM, April 22, 2022 /PRNewswire/ -- The shareholders of Cantargia AB (publ) are invited to the annual general meeting on Monday, 23 May 2022, at 16.00 CET at Ideon Gateway, Scheelevägen 27, Lund, Sweden.

Right to participate and notice

Shareholders who wish to participate in the meeting must:

Nominee registered shares

Shareholders whose shares are nominee registered with a bank or other nominee, must, in order to be entitled to participate at the meeting, re-register the shares in their own name. Such re-registration, which may be temporary, must be completed on Friday, 13 May 2022. Accordingly, shareholders who wish to re-register their shares must inform the nominee of this request well in advance of the said date. Such registration made no later than the second banking day after 13 May 2022 are taken into account in the production of the share register.

Proxy etc.

Shareholder represented by a proxy shall issue a power of attorney for the proxy. If the power of attorney is issued on behalf of a legal entity, a registration certificate or the equivalent indicating the authorized signatories of the legal entity must be enclosed. The original power of attorney, and any registration certificate or the equivalent document, shall be sent to the company at the address above well in advance of the meeting. Proxy forms are available at the company's website www.cantargia.com and will, upon request, be sent by regular mail to shareholders stating their postal address.

Number of shares and votes

As per the date of this notice, there are 100,192,737 outstanding shares and votes in the company. The company holds no treasury shares.  

Proposed agenda:

1.   Opening of the meeting

2.   Election of chairman of the meeting

3.   Preparation and approval of voting list

4.   Approval of the agenda

5.   Election of one or two persons to verify the minutes

6.   Determination of whether the meeting has been duly convened

7.   Presentation of the annual report and auditor's report

8.  Resolutions

      1.   on the adoption of the income statement and the balance sheet
      2.   on the disposition of the company's results as per the adopted balance sheet
      3.   on discharge from liability of the members of the board of directors and the CEO

9. Determination of the number of members of the board of directors and auditors

10. Determination of fees to be paid to the board of directors and auditor

11. Election of the members of the board of directors and auditor

      1. Re-election of Patricia Delaite as board member
      2. Re-election of Thoas Fioretos as board member
      3. Re-election of Karin Leandersson as board member
      4. Re-election of Anders Martin-Löf as board member
      5. Re-election of Flavia Borellini as board member
      6. Re-election of Magnus Nilsson as board member
      7. Re-election of Damian Marron as board member
      8. Re-election of Magnus Persson as board member
      9. Re-election of Magnus Persson as chairman of the board
      10. Re-election of Öhrlings PricewaterhouseCoopers AB as auditor

12. Resolution on the nomination committee

13. Presentation of the board of directors' remuneration report for approval

14. The board of directors' proposal regarding implementation of a long term share based incentive scheme

15. The board of directors' proposed resolution on share issue authorization

16. Closing of the meeting

Disposition of the company's results (item 8 b)

The board proposes that no dividend shall be distributed, and that the company's accumulated results shall be carried forward.

The nomination committee's proposal (items 2 and 9 - 11)

The nomination committee, consisting of Chairman, Marianne Nilsson (Swedbank Robur Fonder), Jannis Kitsakis (Fourth Swedish National Pension Fund), Mikael Wiberg (Alecta Pensionsförsäkring, Ömsesidigt) and Magnus Persson, chairman of the board, proposes the following:

The proposal regarding the auditor is in accordance with the audit committee's recommendation.

Nomination committee (item 12)

The nomination committee proposes that the annual general meeting resolves:

Share based incentive scheme (item 14)

The board of directors proposes that the annual general meeting resolves to adopt a long-term variable share-based incentive scheme for senior executives and key personnel within the company. The proposal is based on the incentive scheme that was adopted by the 2019, 2020 and 2021 annual general meetings. It has been initiated by Cantargia's board of directors and has been designed in collaboration with external advisors and prepared by the remuneration committee and examined at board meetings.

Purpose and scope of the scheme

In order to create a long-term incentive for the company's management team and to promote investments in and ownership of Cantargia shares, all members of the company's management team, including the CEO, as well as other key personnel will be offered variable long-term remuneration in the form of a group bonus for acquisition of shares of the company (the "Scheme"). The Scheme is a variable long-term remuneration scheme under which the participants commit to use distributed variable cash remuneration to acquire shares in the company. The participants will acquire the shares on the stock market. The Scheme applies in addition to any variable remuneration in accordance with the remuneration guidelines adopted at the 2020 annual general meeting. It is intended that the Scheme shall recur annually.

The maximum pay out to each Scheme participant for 2022 is capped at 10 per cent of the participant's base cash salary. The total size of the Scheme for 2022 is capped at SEK 2,300,000, excluding social security contributions. In case of partial target achievement, a portion of the maximum amount will be distributed.

Performance requirements and target achievement

The Scheme is based on the annual bonus target or targets set up by the company's board of directors and that refer to the company's activities, financial key performance indicators and internal processes. The resolution on the annual amount available under the Scheme will be integrated in the annual evaluation process for the total variable remuneration in order to link annual performances to long-term targets, to increase employee shareholding in Cantargia and to retain competent staff at competitive terms.

Target achievement will be assessed by the company's board of directors in connection with the adoption of the annual report for each year. To be entitled to a portion of the group bonus for acquisition of shares under the Scheme, the employee must be a permanent employee. In addition, the employee must have been employed by the company for at least one year. A draft resolution on which employees that will be subject to the Scheme will be drawn up by the remuneration committee in consultation with the CEO. The board of directors will resolve upon which employees that will be subject to the Scheme.

Distribution and acquisition of Cantargia share

When the target achievement has been determined by the company's board of directors, the amount will be distributed to each participant in the Scheme within four weeks of the adoption of the annual report. The acquisition of shares by the participant shall be made as soon as possible after the distribution from the company. In the event the participant is prevented from acquiring shares of the company, due to for example applicable market abuse regulations, the company's board of directors may permit that the acquisition of shares under the Scheme takes place at a later stage. 

Participants are required to use their entire remuneration under the Scheme, net of tax, to acquire Cantargia shares on the stock market. Shares acquired by a participant under the Scheme must be held by the participant under a three-year period after the distribution.

The company will pay social-security contributions on variable remuneration distributed under the Scheme. However, the remuneration distributed under the Scheme will not entitle to pension contributions or holiday pay in addition to what is provided under mandatory legislation.

Termination of employment or breach of contract

A participant whose employment ceases as a result of termination by the employee or by the company or for other

reasons will be required to continue to hold shares acquired in accordance with the provisions of the Scheme.

In the event a participant violates the terms of the Scheme, for example by failing to provide information on the status of its shareholding, the company may require that the participant sells all shares acquired under the Scheme, whereby the gross amount received by the participant through the sale shall be reimbursed to the company. In the event the participant sells shares in breach of the terms of the Scheme, the participant is required to pay a penalty to the company corresponding to the gross amount that the employee has received through the sale of the shares.

Principles for annual variable remuneration and the Scheme

When designing the annual variable remuneration and the Scheme, the board of directors shall consider introducing conditions which:

Share issue authorization (item 15)

The board of directors proposes that the annual general meeting resolves to authorize to the board, up and until the next annual general meeting, on one or several occasions and with or without pre-emptive rights for shareholders, to resolve on the issue of new shares, provided that such issue or issues may not comprise a total of more than 10 per cent of the number of outstanding shares in the company as per the day of the annual general meeting. It shall also be possible to make such an issue resolution stipulating in-kind payment, the right to offset debt or other conditions.

The purpose of the authorization is to raise working capital for the company. If the board resolves on a share issue with deviation from the shareholders' pre-emptive rights, the reason therefor shall be to raise working capital for the company, to provide new shareholders of strategic importance to the company or to acquire other companies or businesses.


Other information

Complete documentation is available at the company's offices, Scheelevägen 27 in Lund, Sweden, and at the company's website (www.cantargia.com) no later than three weeks prior to the meeting. Copies of the documentation will be sent to shareholders who so request. Shareholders are reminded of their right to require information under Chapter 7 Section 32 of the Swedish Companies Act.

Processing of personal data

For information about the processing of your personal data, please refer to www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. Cantargia's AB (publ) corporate registration number is 556791-6019 and its registered office is in Lund, Sweden.

Lund, April 2022

Cantargia AB (publ)

The board of directors

For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

About Cantargia

Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The lead project, the antibody nadunolimab (CAN04), is being studied clinically in combination with chemotherapy or immune therapy in a series of clinical studies ? CANFOUR, CIRIFOUR, CAPAFOUR, CESTAFOUR and TRIFOUR ? with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia's second project, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at https://cantargia.com/en/.

This information was brought to you by Cision http://news.cision.com


The following files are available for download:


Cantargia Notice AGM 2022 En

These press releases may also interest you

at 23:15
The "Pulmonary Edema Therapeutics Market by Type (Cardiogenic pulmonary edema and Non-cardiogenic pulmonary edema) and Geography (North America, Europe, Asia, and Rest of World (ROW)) - Forecast and Analysis 2022-2026" report has been added to...

at 23:00
A plethysmograph is a non-invasive, low-cost device that is used to measure the volume changes in different parts of the body, resulting from fluctuations in the amount of blood or air. The device uses blood pressure cuffs and sensors. It is used for...

at 22:48
EverVet Partners ("EverVet" or the "Company"), one of the fastest growing veterinary services platforms in the U.S., today announced its partnership with Freeman Spogli & Co. ("Freeman Spogli"), a leading private equity investor in the consumer and...

at 22:12
WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), announced today that it has once again been selected as a constituent of the FTSE4Good Index Series, and is the only...

at 22:00
Endo International plc ("Endo" or the "Company") today announced...

at 21:30
Steady rise in R&D on drug discovery and chronic...

News published on 22 april 2022 at 07:14 and distributed by: